Metformin Pharmacokinetics in Patients With Chronic & Acute Heart Failure

Status Active, not recruiting

Clinical Trial Summary

The study evaluates the pharmacokinetics of metformin in heart failure patients in acute and chronic state in relation to metformin transporter genotypes. Participants have heart failure and type 2 diabetes treated with metformin.

Hypothesis:

Primary: The renal clearance of metformin is decreased in acute state of congestive heart failure compared with chronic state.

Secondary: Metformin trough values in HF patients are influenced by polymorphisms in transporter genes relevant to the pharmacokinetics of metformin.

Clinical Trial Description

Background: Heart failure (HF) is a common disease and diabetes/insulin resistance are present in approximately 50 % of HF patients. Metformin is the most commonly prescribed oral anti-diabetic drug, and a huge inter-individual variability in trough steady-state metformin concentration in type 2 diabetics have been demonstrated. Genetic polymorphisms in metformin transporter genes are likely to have a direct impact on metformin pharmacokinetics and variability in drug responses, but the influence of polymorphisms in these transporter genes on circulating metformin levels is presently unknown in HF patients.

Objectives:

A) To compare the pharmacokinetics of metformin in 12 diabetic patients with HF in acute and chronic state.

B) To investigate the influence of polymorphisms in genes encoding the metformin transporter proteins on metformin trough levels in 150 diabetic HF patients.

Design: An open, single-center study enrolling 12 patients with acute heart failure (study A) and 150 patients with stable chronic heart failure (study B). The participants have diabetes already treated with metformin prior to inclusion. Through repeated blood draws, the concentration of metformin will be determined along with genotyping for metformin transporter genes.

Primary outcome:

Study A: Changes in renal clearance of metformin between patients with acute and chronic heart failure.

Study B: Mean trough steady-state concentrations of metformin with emphasis on the intra-interindividual variability in HF patients. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02797340
Study type	Interventional
Source	Aarhus University Hospital
Contact
Status	Active, not recruiting
Phase	Phase 4
Start date	January 11, 2016
Completion date	April 30, 2018

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT03227393` - The Effect of Yoga on Cardiac Sympathetic Innervation Evaluated by I-123 mIBG	N/A
Recruiting	`NCT04528004` - Mechanistic Studies of Nicotinamide Riboside in Human Heart Failure	Early Phase 1
Recruiting	`NCT04703842` - Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction	Phase 1/Phase 2
Recruiting	`NCT04522609` - Electrostimulation of Skeletal Muscles in Patients Listed for a Heart Transplant	N/A
Completed	`NCT05475028` - Network Medicine Approaches to Classify Heart Failure With PReserved Ejection Fraction by Signatures of DNA Methylation and Point-of-carE Risk calculaTors (PRESMET)
Not yet recruiting	`NCT06240403` - Digoxin and Senolysis in Heart Failure and Diabetes Mellitus	Phase 2
Not yet recruiting	`NCT05988749` - Digital Remote Home Monitoring for Heart Failure	N/A
Recruiting	`NCT04950218` - The Psoriasis Echo Study
Suspended	`NCT04701112` - Acute Hemodynamic Effects of Pacing the His Bundle in Heart Failure	N/A
Completed	`NCT03305692` - ECG Belt vs. Echocardiographic Optimization of CRT	N/A
Recruiting	`NCT05933083` - MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation	N/A
Enrolling by invitation	`NCT03903107` - The Fluoroless-CSP Trial Using Electroanatomic Mapping	N/A
Withdrawn	`NCT04872959` - TRANSFORM Heart Failure With Reduced Ejection Fraction	N/A
Completed	`NCT02920918` - Treatment of Diabetes in Patients With Systolic Heart Failure	Phase 4
Completed	`NCT02334891` - Kyoto Congestive Heart Failure Study
Recruiting	`NCT03553303` - Pharmacodynamic Effects of Sacubitril/Valsartan on Natriuretic Peptides, Angiotensin and Neprilysin	Phase 4
Recruiting	`NCT04083690` - Multi-lead ECG to Effectively Optimize Resynchronization Devices: New CRT Recipients	N/A
Recruiting	`NCT03830957` - Efficacy and Safety of Ivabradine to Reduce Heart Rate Prior to Coronary CT-angiography in Advanced Heart Failure: Comparison With β-Blocker	N/A
Recruiting	`NCT06121323` - Physiological Effects of Lactate in Individuals With Chronic Heart Failure	N/A
Completed	`NCT03351283` - Effect of Sodium Intake on Brain Natriuretic Peptide Levels in Patients With Heart Failure	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Metformin Pharmacokinetics in Patients With Chronic and Acute Heart Failure — MetKin

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms